Moreover, the authors suggest potential strategies, such as rituximab, antibodies specific against FcγRIIb, might be able to enhance the IFN response and restore the weakened antiviral immune responses in patients with severe COVID-19. This evidence concerns the gene IFNA1 and COVID-19.